Histone deacetylase inhibitors VPA and WT161 ameliorate the pathological features and cognitive impairments of the APP/PS1 Alzheimer’s disease mouse model by regulating the expression of APP secretases. This evidence concerns the gene PSEN1 and early-onset autosomal dominant Alzheimer disease.